scholarly journals Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy

2010 ◽  
Vol 5 (1) ◽  
pp. 43 ◽  
Author(s):  
Su Jung Shim ◽  
Jihye Cha ◽  
Woong Sub Koom ◽  
Gwi Eon Kim ◽  
Chang Geol Lee ◽  
...  
Head & Neck ◽  
2009 ◽  
pp. NA-NA ◽  
Author(s):  
Tseng-Cheng Chen ◽  
Chi-Te Wang ◽  
Jenq-Yuh Ko ◽  
Pei-Jen Lou ◽  
Tsung-Lin Yang ◽  
...  

2021 ◽  
Vol 10 (1) ◽  
pp. 1882743
Author(s):  
C. Phanthunane ◽  
R. Wijers ◽  
M. de Herdt ◽  
T.P.M. Langeveld ◽  
S. Koljenovic ◽  
...  

2021 ◽  
Vol 37 (1) ◽  
Author(s):  
Sidharth Pant ◽  
Punita Lal ◽  
Shagun Misra ◽  
Piyush Gupta ◽  
K. J. Maria Das ◽  
...  

Abstract Background The purpose of the study was to evaluate survival outcomes in post-operative oral tongue cancer patients undergoing adjuvant radiotherapy (RT) at a tertiary cancer care center and to critically review the impact of various clinical-pathological factors on recurrence and survival. Demographic factors, stage of all the histology proven oral tongue cancer, and treatment details were documented. Overall survival (OS) and recurrence-free survival (RFS) were analyzed along with the potential prognostic factors affecting outcome. Results One hundred forty-four post-operative oral tongue cancer patients referred to our department for adjuvant treatment were evaluated. Median age at presentation was 45 years. Forty-seven patients had pathological early stage disease (stages I and II) and 95 had locally advanced (stages III and IV) disease while post-op details were not present in 2 patients. At a median follow-up of 87 months (60–124) of alive patients, the median RFS for entire cohort was 62 months while median OS was 74 months respectively. Age, perineural invasion (PNI), and grade of the tumor emerged as independent prognostic factors for OS and RFS. Among patients with early stage disease, depth of invasion (DOI), age, and PNI were found as independent prognostic factors for RFS and OS. In locally advanced disease, higher grade, age, and PNI independently impacted the respective survival end points. Conclusions Age (> 45 years), higher grade, and presence of PNI showed inferior survival outcomes across the sub-groups (early versus locally advanced disease). This may warrant adjuvant treatment intensification. DOI > 10 mm was particularly found to worsen survival in early node negative SCC oral tongue patients.


Oral Diseases ◽  
2018 ◽  
Vol 24 (7) ◽  
pp. 1198-1203 ◽  
Author(s):  
Maheer M. Masood ◽  
Douglas R. Farquhar ◽  
Jessica P. Vanleer ◽  
Samip N. Patel ◽  
Trevor G. Hackman

2013 ◽  
Vol 148 (5) ◽  
pp. 792-796 ◽  
Author(s):  
Ryan Li ◽  
Wayne M. Koch ◽  
Carole Fakhry ◽  
Christine G. Gourin

2011 ◽  
Vol 138 (2) ◽  
pp. 341-346 ◽  
Author(s):  
Liuyang Zhang ◽  
Xuan Zhou ◽  
Xiaofeng Yao ◽  
Yansheng Wu ◽  
Qiang Zhang ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3235
Author(s):  
Alhadi Almangush ◽  
Ibrahim O. Bello ◽  
Ilkka Heikkinen ◽  
Jaana Hagström ◽  
Caj Haglund ◽  
...  

Although patients with early-stage oral tongue squamous cell carcinoma (OTSCC) show better survival than those with advanced disease, there is still a number of early-stage cases who will suffer from recurrence, cancer-related mortality and worse overall survival. Incorporation of an immune descriptive factor in the staging system can aid in improving risk assessment of early OTSCC. A total of 290 cases of early-stage OTSCC re-classified according to the American Joint Committee on Cancer (AJCC 8) staging were included in this study. Scores of tumor-infiltrating lymphocytes (TILs) were divided as low or high and incorporated in TNM AJCC 8 to form our proposed TNM-Immune system. Using AJCC 8, there were no significant differences in survival between T1 and T2 tumors (p > 0.05). Our proposed TNM-Immune staging system allowed for significant discrimination in risk between tumors of T1N0M0-Immune vs. T2N0M0-Immune. The latter associated with a worse overall survival with hazard ratio (HR) of 2.87 (95% CI 1.92–4.28; p < 0.001); HR of 2.41 (95% CI 1.26–4.60; p = 0.008) for disease-specific survival; and HR of 1.97 (95% CI 1.13–3.43; p = 0.017) for disease-free survival. The TNM-Immune staging system showed a powerful ability to identify cases with worse survival. The immune response is an important player which can be assessed by evaluating TILs, and it can be implemented in the staging criteria of early OTSCC. TNM-Immune staging forms a step towards a more personalized classification of early OTSCC.


2021 ◽  
Author(s):  
Marta Tagliabue ◽  
Pietro Belloni ◽  
Rita De Berardinis ◽  
Sara Gandini ◽  
Francesco Chu ◽  
...  

Oral Oncology ◽  
2017 ◽  
Vol 67 ◽  
pp. 146-152 ◽  
Author(s):  
Joseph E. Tota ◽  
William F. Anderson ◽  
Charles Coffey ◽  
Joseph Califano ◽  
Wendy Cozen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document